Supraphysiologic Testosterone Solutions for Enzalutamide-resistant Prostate Cancer

被引：5
|
作者：
Thomas, Lewis [1 ,2 ]
Baratchian, Mehdi [1 ]
Sharifi, Nima [1 ,2 ,3 ]
机构：
[1] Cleveland Clin, Lerner Res Inst, Genitourinary Malignancies Res Ctr, Cleveland, OH 44106 USA
[2] Cleveland Clin, Dept Urol, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA
[3] Cleveland Clin, Dept Hematol & Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
EUROPEAN UROLOGY | 2020年 / 77卷 / 02期
关键词：
D O I：
10.1016/j.eururo.2019.07.037
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：156 / 157
页数：2
相关论文
共 50 条
  • [41] Targeting binding function-3 site on the androgen receptor to treat Enzalutamide-resistant prostate cancer
    Munuganti, Ravi Shashi Nayana
    Hassona, Mohamed D. H.
    Leblanc, Eric
    Guns, Emma T.
    Rennie, Paul S.
    Cherkasov, Artem
    CANCER RESEARCH, 2015, 75
  • [42] CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
    Chen, Xi
    Wu, Yechen
    Wang, Xinan
    Xu, Chengdang
    Wang, Licheng
    Jian, Jingang
    Wu, Denglong
    Wu, Gang
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [43] Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer
    Daksh Thaper
    Sepideh Vahid
    Ramandeep Kaur
    Sahil Kumar
    Shaghayegh Nouruzi
    Jennifer L. Bishop
    Martin Johansson
    Amina Zoubeidi
    Scientific Reports, 8
  • [44] Downregulation of EZH2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer
    Zhang, Zhuangzhuang
    Wang, Xinyi
    Kim, Miyeong
    He, Daheng
    Wang, Chi
    Fong, Ka Wing
    Liu, Xiaoqi
    PROSTATE, 2023, 83 (15): : 1458 - 1469
  • [45] Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer
    Abudurexiti, Mierxiati
    Zhu, Wenkai
    Wang, Yuchen
    Wang, Jun
    Xu, Wenhao
    Huang, Yongqiang
    Zhu, Yao
    Shi, Guohai
    Zhang, Hailiang
    Zhu, Yiping
    Shen, Yijun
    Dai, Bo
    Wan, Fangning
    Lin, Guowen
    Ye, Dingwei
    PROSTATE, 2020, 80 (12): : 950 - 961
  • [46] CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
    Xi Chen
    Yechen Wu
    Xinan Wang
    Chengdang Xu
    Licheng Wang
    Jingang Jian
    Denglong Wu
    Gang Wu
    European Journal of Medical Research, 27
  • [47] Overcoming enzalutamide-resistant castration-resistant prostate cancer by targeting transcriptional 71 repressor BCL-6.
    Hongo, Hiroshi
    Kosaka, Takeo
    Miyazaki, Yasumasa
    Kikuchi, Eiji
    Oya, Mototsugu
    CANCER SCIENCE, 2018, 109 : 975 - 975
  • [48] Daclatasvir, an Antiviral Drug, Downregulates Tribbles 2 Pseudokinase and Resensitizes Enzalutamide-Resistant Prostate Cancer Cells
    Monga, Jitender
    Valeriote, Frederick
    Hwang, Clara
    Gadgeel, Shirish
    Ghosh, Jagadananda
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (03) : 381 - 392
  • [49] Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer
    Toren, Paul
    Kim, Soojin
    Johnson, Fraser
    Zoubeidi, Amina
    PLOS ONE, 2016, 11 (04):
  • [50] Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer
    Thaper, Daksh
    Vahid, Sepideh
    Kaur, Ramandeep
    Kumar, Sahil
    Nouruzi, Shaghayegh
    Bishop, Jennifer L.
    Johansson, Martin
    Zoubeidi, Amina
    SCIENTIFIC REPORTS, 2018, 8
12345